Abstract Body

Background

In 2021, antiretroviral treatment (ART) recommendations for infants were updated from lopinavir/r (LPV/r) to dolutegravir (DTG)-based regimens from 4 weeks of age and 3kg body weight. DTG-based regimens are expected to result in improved treatment efficacy due to increased potency, high resistance barrier, and improved practicality.

Methods

We conducted two cluster-randomized trials at primary and secondary healthcare facilities in Mozambique and Tanzania to identify neonatal HIV between birth and 3 months of age. The LIFE Study (enrolment 2019-2021, n=6602) offered neonatal point-of-care (PoC) test-and-treat at birth in the intervention arm and from 4-6 weeks of age in the standard of care arm. The LIFE2Scale Study (enrolment 2023-2025, n=3715) implemented birth test-and-treat based on high-risk criteria for vertical HIV transmission within a hub-and-spoke delivery model. In both studies, neonates with HIV received zidovudine, lamivudine, and nevirapine at birth, and were switched to or initiated on abacavir and lamivudine in combination with LPV/r granules (LIFE) or DTG (LIFE2Scale). ART dosing was based on WHO weight bands. Viral load monitoring was performed at 3, 6 and 12 months of age. We report risk ratios (RR) with 95% confidence intervals (CI) of infants virally suppressed (<1000 copies/ml) for DTG versus LPV/r-based regimens for month 3 and 6.

Results

In LIFE, 125 infants acquired HIV by 3 months of life (transmission rate 1.89%; 95% CI: 1.58, 2.25), with 37 (29.8%) initiating ART at birth and 81 (64.8%) from week 4.  In LIFE2Scale, 39 infants acquired HIV by 3 months (transmission rate 1.15%; 95% CI: 0.78, 1.52), with 11 (28.2%) initiating ART at birth and 28 (71.8%) from week 4. The median time between HIV diagnosis and ART initiation in LIFE was 0 days, [IQR: 0, 0], and in the hub-and-spoke model in LIFE2Scale 4 days [IQR: 0, 12]. Viral suppression for DTG (LIFE2Scale) versus LPV/r (LIFE) was 48.1% versus 26.1% at month 3 (RR: 1.695, 95% CI: 1.015, 2.831; p=0.065) and 73.7% versus 31.1% at month 6 (RR: 2.364, 95% CI: 1.542, 3.623; p=0.001). All infant treatment regimens were well tolerated.  

Conclusions

PoC test-and-treat at birth was feasible in low resource settings and resulted in immediate ART initiation within primary and secondary healthcare facilities. DTG-based regimens were associated with improved viral suppression compared to LPV/r granule-based regimens at months 3 and 6, supporting recent treatment guideline modification.